Akero Therapeutics, Inc.
AKRODelisted Dec 9, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001744659
Akero Therapeutics, Inc. was delisted on Dec 9, 2025; its insiders filed their last Form 4 on Dec 9, 2025; 265 institutions reported holding it in 13F filings for Q3 2025, worth $4.34B in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Akero Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Akero Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Harrison Seth Loring | Director | 0 | Dec 9, 2025 | 1 |
| Iwicki Mark T | Director | 0 | Dec 9, 2025 | 1 |
| Henderson Jane | Director | 0 | Dec 9, 2025 | 1 |
| Gangloff Scott A. | Chief Technology Officer | 0 | Dec 9, 2025 | 1 |
| Graham G. Walmsley | Director | 0 | Dec 9, 2025 | 2 |
| Cheng Andrew | President and CEO | 0 | Dec 9, 2025 | 5 |
| White William Richard | Chief Financial Officer | 0 | Dec 9, 2025 | 1 |
| Yale Catriona | Chief Development Officer | 0 | Dec 9, 2025 | 2 |
| Rolph Timothy | Chief Scientific Officer | 0 | Dec 9, 2025 | 4 |
| Young Jonathan | Chief Operating Officer | 0 | Dec 9, 2025 | 3 |
| Heyman Tomas J. | Director | 0 | Dec 9, 2025 | 1 |
| Xu Yuan | Director | 0 | Dec 9, 2025 | 1 |
| Judy Chou | Director | 0 | Dec 9, 2025 | 1 |
| Lamy Patrick | See Remarks | 0 | Dec 9, 2025 | 1 |
| Ezbon International Ltd | Other: Former 10% owner | 3,271,829Indirect | Dec 5, 2022 | 0 |
| Blue Horizon Enterprise Ltd | Other: Former 10% owner | 3,271,829Indirect | Dec 5, 2022 | 0 |
| Montrago Trustees Ltd | Other: Former 10% owner | 3,271,829Indirect | Dec 5, 2022 | 0 |
| Skorpios Trust | Other: Former 10% owner | 3,271,829Indirect | Dec 5, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 2021 (view filing) | Sep 1 | 2 days | Young JonathanChief Operating Officer | SSale | −12.5K | $24.04 | −$300.5K | −7.2%160.5K after | |
| Sep 3, 2021 (view filing) | Sep 1 | 2 days | White William RichardChief Financial Officer | SSale | −8.56K | $24.00 | −$205.4K | −72.3%3.28K after | |
| Sep 3, 2021 (view filing) | Sep 2 | 1 day | Cheng AndrewPresident & CEO | SSale | −17.5K | $23.89 | −$418.1K | −5.4%308.5K after | |
| Aug 17, 2021 (view filing) | Aug 16 | 1 day | Yale CatrionaChief Development Officer | SSale | −10.0K | $18.79 | −$187.9K | −6.4%145.9K after | |
| Aug 4, 2021 (view filing) | Aug 2 | 2 days | White William RichardChief Financial Officer | SSale | −4.44K | $22.03 | −$97.8K | −57.5%3.28K after | |
| Aug 4, 2021 (view filing) | Aug 3 | 1 day | Cheng AndrewPresident & CEO | SSale | −17.5K | $20.83 | −$364.6K | −5.1%326.0K after | 2 lots |
| Jul 19, 2021 (view filing) | Jul 15 | 4 days | Yale CatrionaChief Development Officer | SSale | −10.0K | $20.90 | −$209.0K | −6.0%155.9K after | |
| Jul 8, 2021 (view filing) | Jul 6 | 2 days | White William RichardChief Financial Officer | SSale | −6.50K | $24.52 | −$159.4K | −66.5%3.28K after | |
| Jul 6, 2021 (view filing) | Jul 2 | 4 days | Cheng AndrewPresident & CEO | SSale | −17.5K | $24.78 | −$433.6K | −4.9%342.5K after |